Brand Name(s): CI-1011
CAS nş: 166518-60-1
(a vah si mide)
What is Avasimibe?
Avasimibe is an ACAT (acyl-coenzyme A: cholesterol acyltransferase) inhibitor that was developed to treat heart disease, prevent the progression of atherosclerosis, as well as lower cholesterol.
After having undergone the phase III clinical trials in 2002, Pfizer decided to discontinue its development.
Latest News
Atherosclerosis Symptoms, Causes, prevention and Treatment
By atherosclerosis the inside of the arteries are thickened, hardened and stiffened, causing the...
[more]Failure of ACAT Inhibition to Retard Atherosclerosis
Medical management of atherosclerosis is based on the control of its risk factors (dyslipidemia,...
[more]ACAT inhibitor unsuccessful at limiting atherosclerosis
Trial findings released last week at the American Heart Association scientific sessions 2005 in...
[more]Pfizer's Cardiovascular Failure
New York - Nobody wins all the time--not even the world's largest drug company. Yet Pfizer's...
[more]